

DAFTAR PUSTAKA

1. World Health Organization. Medication Without Harm: Policy Brief [Internet]. 2023 [cited 2025 Sep 23]. Available from: <https://www.who.int/initiatives/medication-without-harm>
2. Global Burden of Preventable Medication-Related Harm in Health Care: A Systematic Review [Internet]. Geneva: World Health Organization; 2023. 1–42 p. Available from: <https://www.who.int/publications/i/item/9789240088887>
3. Alghamdi AA, Keers RN, Sutherland A, Ashcroft DM. Prevalence and Nature of Medication Errors and Preventable Adverse Drug Events in Paediatric and Neonatal Intensive Care Settings: A Systematic Review. *Drug Saf* [Internet]. 2019;42(12):1423–36. Available from: <https://doi.org/10.1007/s40264-019-00856-9>
4. Yulistiani, Lestari K, Utomo FN, Sampurna MTA. Quantitative and qualitative analysis of antibiotic use among neonatal patients in teaching hospitals in Indonesia. *Pharmacia*. 2024;71:1–9.
5. Hollander EM, van Tuinen EL, Schölvinck EH, Bergman KA, Bourgonje AR, Gracchi V, et al. Evaluation of Dosing Guidelines for Gentamicin in Neonates and Children. *Antibiotics*. 2023;12(5).
6. McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. *Pediatr Nephrol*. 2017;32(11):2015–25.
7. Steyger PS. Mechanisms of Ototoxicity and Otoprotection. *Otolaryngol Clin North Am*. 2021;54(6):1101–15.
8. Salehifar E, Rafati MR. Extended-Interval Dosing of Aminoglycosides in Pediatrics: A Narrative Review. *J Pediatr Rev*. 2015;3(2).
9. Mardatillah M, Postma MJ, Yosmar R, Fitria N. Optimizing Antibiotic Therapy in NICU and PICU: Clinical and Economic Impact of IV Admixture Implementation. In: *Beyond The Limit: Advancements and Innovation of Asian Clinical Pharmacy* [Internet]. Denpasar: Asian Conference On Clinical Pharmacy Indonesia; 2025. p. 544. Available from: <https://publications.waim.org.my/index.php/jims/article/view/132/100>
10. Ahmad RSM, Nugroho NP, Niazta NA, Putri RS, Rumah P, Kprs S, et al. Perbandingan Dispensing Error antara Bangsal dengan Unit Dose Dispensing dan tanpa Unit Dose Dispensing di RSM Ahmad Dahlan Comparison of Dispensing error between Ward with Unit Dose Dispensing and without Unit Dose mengakibatkan cedera pada pasien akibat. *Medica Arter*. 2020;2(2):71–9.
11. Rachmawati R, Adiana S. Evaluasi Kesesuaian Penerapan Sistem Distribusi Unit Dose Dispensing (UDD) Berdasarkan Standar Prosedur Operasional Di Ruang Rawat Inap Rumah Sakit (X) Periode Juni – Agustus 2022. *Indones J Heal Sci*. 2023;3(2a):180–4.
12. Wijayanto Y, Wahyono D, Genatrika E. Implementasi dan Efektivitas Sistem Unit Dose Dispensing Dalam Meningkatkan Keselamatan Pasien di Rumah Sakit. *Syntax Lit ; J Ilm Indones*. 2025;10(5):4808–21.
13. Vold JH, Aas C, Skurtveit S, Odsbu I, Chalabianloo F, Reutfors J, et al.

- Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: A register-based prospective cohort study in Norway and Sweden from 2015 to 2017. *BMJ Open*. 2020;10(8):1–10.
14. Gallina M, Testagrossa M, Provenzani A. Unit dose drug dispensing systems in hospitals: a systematic review of medication error reduction and cost-effectiveness. *Eur J Hosp Pharm* [Internet]. 2025;1–8. Available from: doi:10.1136/ejhpharm-2024-004444
 15. Haddad MF, Abdullah BA, AIObeidi HA, Saadi AM, Haddad MF. Antibiotic classification, mechanisms, and indications: A review. *Int J Med All Body Heal Res*. 2024;5(3):39–46.
 16. Kapoor G, Saigal S, Elongavan A. Action and resistance mechanism of antibiotics: A guide for clinicians. *J Anaesthesiol Clin Pharmacol* [Internet]. 2017;33(3):300–5. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC5672523/pdf/JOACP-33-300.pdf>
 17. Etebu E, Ibemologi Arikekpar. Classification and mechanisms of action with emphasis on molecular perspectives. *Int J Appl Microbiol Biotechnol Res*. 2016;4(January 2016):90–101.
 18. Webster CM, Shepherd M. A mini-review: environmental and metabolic factors affecting aminoglycoside efficacy. *World J Microbiol Biotechnol* [Internet]. 2023;39(1):1–13. Available from: <https://doi.org/10.1007/s11274-022-03445-8>
 19. Wachino JI, Doi Y, Arakawa Y. Aminoglycoside Resistance: Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases. *Infect Dis Clin North Am*. 2020;34(4):887–902.
 20. Pacifici GM, Marchini G. Clinical Pharmacology of amikacin in infants and children. *Clin Med Investig*. 2019;5(1):1–14.
 21. Kros CJ, Steyger PS. Aminoglycoside- and cisplatin-induced ototoxicity: Mechanisms and otoprotective strategies. *Cold Spring Harb Perspect Med*. 2019;9(11):1–18.
 22. Danisa Hasmuddin A, Seniwati T, Iswanti Afelya T. Children Mortality in Pediatric Intensive Care Unit (PICU): An Overview. *J Kesehatan Pasak Bumi Kalimantan* [Internet]. 2022;5(1):22–7. Available from: <http://e-journals.unmul.ac.id/index.php/JKPBK>
 23. Estiningsih D, Puspitasari I, Nuryastuti T. Identifikasi Infeksi Multidrug-Resistant Organisms (MDRO) Pada Pasien Yang Dirawat di Bangsal Neonatal Intensive Care Unit (NICU) RSUP DR. Soeradji Tirtonegoro Klaten. *J Manaj dan Pelayanan Farm (Journal Manag Pharm Pract* [Internet]. 2016;6(3):243–8. Available from: <https://dev.jurnal.ugm.ac.id/jmpf/article/view/29417/17566%0Ahttps://dev.jurnal.ugm.ac.id/jmpf/article/view/29417>
 24. Butranova OI, Ushkalova EA, Zyryanov SK, Chenkurov MS. Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants. *Biomedicines*. 2023;11(3):1–44.
 25. Tarigan PB, Posangi J, Mambo CD. Karakteristik Pasien dan Penggunaan Antibiotik di Ruang Pediatric Intensive Care Unit (PICU) Salah Satu Rumah Sakit Swasta di Sulawesi Utara. *e-CliniC*. 2024;12(3):408–13.

26. Ruggiero A, Ariano A, Triarico S, Capozza MA, Ferrara P, Attinà G. Neonatal pharmacology and clinical implications. *Drugs Context*. 2019;8:1–9.
27. Chapron BD, Chapron A, Leeder JS. Recent advances in the ontogeny of drug disposition. *Br J Clin Pharmacol*. 2022;88(10):4267–84.
28. Steindl-Schönhuber T, Drechsel T, Gittler G, Weidmann AE. Hospital pharmacy implementation of a unit dose dispensing system: A qualitative interview study to determine experiences, views and attitudes of nursing staff. *Explor Res Clin Soc Pharm*. 2025;17(January).
29. Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmaco-economic analysis: The case of pharmacist-led interventions. *Pharm Pract (Granada)*. 2021;19(1):1–10.
30. Syavardie, Y., Mardatillah, Yuniar, C. R., Serdiani, Arief, I., Suhery, D., Ersa, C.B., Fitria, N., Anggraini, L.F., Anggoro, A., Ihsan M. *Farmakoekonomi*. Yogyakarta: PT Penamuda Media; 2024.
31. Kemenkes RI. *Pedoman Umum Penilaian Teknologi Kesehatan Di Indonesia*. Jakarta: Lembaga Penerbit BKPK; 2022.
32. Kemenkes RI. *Pedoman Penerapan Kajian Farmakoekonomi* [Internet]. Jakarta: Kementerian kesehatan RI; 2013. 1–96 p. Available from: <chrome-native://pdf/link?url=content%3A%2F%2Fmedia%2Fexternal%2Fdownloads%2F1000325581>
33. Kemenkes RI. *Buku Panduan Penilaian Teknologi Kesehatan: Efektivitas Klinis dan Evaluasi Ekonomi*. Jakarta: Komite Penilaian Teknologi Kesehatan; 2017. 1–175 p.
34. Turner HC, Archer RA, Downey LE, Isaranuwatthai W, Chalkidou K, Jit M, et al. An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations. *Front Public Heal*. 2021;9(August):1–17.
35. Brent RJ. Cost-Benefit Analysis versus Cost-Effectiveness Analysis from a Societal Perspective in Healthcare. *Int J Environ Res Public Health*. 2023;20(5).
36. Robinson LA, Hammitt JK, Cecchini M, Chalkidou K, Claxton K, Cropper ML, et al. Reference Case Guidelines for Benefit-Cost Analysis in Global Health and Development. *SSRN Electron J*. 2022;(May).
37. Shahnaz K, Keri L. Review Artikel: Kajian Farmakoekonomi yang Mendasari Pemilihan Pengobatan di Indonesia. *Farmaka*. 2018;16(3):134–45.
38. Lembaga Kebijakan Pengadaan Barang/Jasa Pemerintah. *Katalog Elektronik Nasional (INAPROC)*. 2025. e-katalog. Available from: <https://katalog.inaproc.id/search?keyword=amikasin+inj+&page=1>
39. Kementerian Kesehatan Republik Indonesia. *e-fornas* [Internet]. 2024. Available from: <https://e-fornas.kemkes.go.id/guest/daftar-obat>
40. MIMS Philippines. *MIMS Online*. 2025. Amikacin sulfate. Available from: <https://www.mims.com/philippines/drug/info/amikacide?type=full>
41. MIMS Thailand. *MIMS Online*. 2025. Gentamisin TP. Available from: <https://www.mims.com/thailand/drug/info/gentamicin-t-p?type=full>
42. Bereda G. *Pediatrics : pharmacokinetics and dose calculation*. *J Pediatr neonatal Cares* [Internet]. 2022;12(2):1–8. Available from:

- https://www.researchgate.net/publication/362139426_Pediatrics_Pharmacokinetics_and_dose_calculation
43. Microbiol C, Balkhy HH, Saed A El, Alshehri A, Alshaalan M, Hijazi O, et al. Antimicrobial consumption in three pediatric and neonatal intensive care units in Saudi Arabia : 33 - month surveillance study. *Ann Clin Microbiol Antimicrob* [Internet]. 2019;2:2–9. Available from: <https://doi.org/10.1186/s12941-019-0320-2>
 44. Asaduzzaman M, Rahaman M zamiur, Afrin S, Ara R, Mehmood S, Boriani E, et al. Antibiotic prescribing patterns in the community and primary care settings through a gender lens : A systematic review settings through a gender lens : A systematic review. *Public Health* [Internet]. 2025;242:311–8. Available from: <https://researchrepository.universityofgalway.ie/server/api/core/bitstreams/921529e0-62dc-43ca-8bdb-084c27d9ee71/content>
 45. Martin-mons S, Gouyon B, Lorrain S, Abasse S, Binson G, Brat R, et al. Prescription of Aminoglycosides in 23 French Neonatal Intensive Care Units. 2021;2020.
 46. Le J, Bradley JS. Optimizing Antibiotic Drug Therapy in Pediatrics : Current State and Future Pharmacokinetics : Alterations Stemming. 2018;(March).
 47. Gourishankar A, Agbasi A, Kain C, Lin E. Antibiotic exposure in hospitalized pediatric patients in the United States: prevalence and length of stay. *Expert Rev Anti Infect Ther* [Internet]. 2020;0(0). Available from: <https://doi.org/10.1080/14787210.2020.1787833>
 48. Herrmann S. Introduction of Unit-Dose Care in the 1 , 125 Bed Teaching Hospital : Practical Experience and Time Saving on Wards. 2024;(March):1137–45.
 49. Kusumahati E, Anita D, Patrisia M. Gambaran Sistem Distribusi Unit Dose Dispensing (UDD) Terhadap Retur Obat Injeksi Generik di Instalasi Farmasi Rawat Inap Salah Satu Rumah Sakit Swasta di Kota Bandung. *J Ilm Manuntung*. 2021;7(2):236–9.
 50. Jessurun GJ, Hunfeld N, Dijk M Van, Bemt P, Polinder S. Cost-effectiveness of central automated unit dose dispensing with barcode-assisted medication administration in a hospital setting. *Res Soc Adm Pharm*. 2022;18(July):3980–7.
 51. Nwafuru SK, Osaremwindi M, Ukeredi RE, Ezechukwu OD. Impact Assessment Of Unit Dose Dispensing System Among Medical Inpatients Of A Nigerian Federal. *Niger J Clin Pharm Ther*. 2023;2(1).
 52. Lukanawonakul A, Thanasitthichai S, Butthongkomvong K, Sribundit N. Economic evaluation of a robotic chemotherapy compounding system and its service expansion to network hospital in Thailand. 2025;7.
 53. Hänninen K, Ahtiainen HK, Suvikas- EM, Tötterman AM. Automated unit dose dispensing systems producing individually packaged and labelled drugs for inpatients : a systematic review. 2023;127–35.